Biogen Inc【BIIB】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

Upcoming community events will inform plans to create more equitable flying experiences for passengers with...

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than...

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a...

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS...

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous...

Biogen Reports Progress on Corporate Responsibility Priorities

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the...

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of...

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced...

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

New data advances understanding of new approaches to treating Alzheimer’s diseaseResearch on disease...

👍️0

tredenwater2 4月前

Biib must be out of AD bullets…or actually more like BB’s. With 3-4 20 billion dollar swap trading by HF’s the stock is at multiyear lows. It used to hit $200 and would spring up like clock work.

I hope the validation of our science upon MAA approval at AVXL puts a fork in this company making their pipeline overly insignificant.

👍️0

Monksdream 6月前

BIIB still in bear mode

👍️0

avxl_going_long 9月前

https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm

👍️0

Monksdream 10月前

BIIB still in bear mode

👍️0

Lonewolf1 2年前

Oops…. Another HOD

$10

👍️0

MiamiGent 2年前

BIIB Took a little short AH when it's PDUFA decision was mixed
Shorted at 261.50
Closed out AH at 260.87
Not expecting more than a hamburger and fries. BIOGEN INC is huge company and hard to move its dial.

https://stockcharts.com/h-sc/ui?s=BIIB

👍️0

Mr. Zen 2年前

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

👍️0

Mr. Zen 2年前

This board is about to light up!

👍️0

tredenwater2 2年前

Well Biib and Esaly look to be joined at the hip. And here I thought they were two profitable independent companies. Amazing how they have traded virtually identical as if this is their only ticket left to punch.

And why no run up? Is the gig finally up Mc? Maybe their MM “cried wolf” one too many times.

👍️0

McMagyar 2年前

Who wants to be the lead Buffalo today?
Can you stampede the herd of bio thieves over the $30Billion dollar cliff for the fourth time? Maybe! But you are stealing from treatments and patients and all those who love them.. for nothing..
The best aduscam will ever be is an adjuvant to anavex or cassava..

The BEST..

Don’t do it again .. even if you can..

Please

👍️0

tredenwater2 2年前

Funds swapping spit again, nothing new.

👍️0

McMagyar 2年前

Imagine if fda had denied?
Pyrrhic Victory defined

👍️0

tredenwater2 2年前

Amen MC. Im surprised at only a 3.5% rise in pps. Wheres the 10-20 billion MC increase enthusiasm like 4 times before? Maybe they will have to PR it again in a week so the market “gets it”.

👍️0

McMagyar 2年前

Ps not short Biogen..
Just long dementia

👍️ 1

McMagyar 2年前

Investors can make a difference as to what our healthcare system becomes..

You and your decisions affect millions of lives..

Let Blarcamesine , succesful TLD ,
Be the rule of the day for our sick..

See if other drugs help people once their homeostasis is secured..maybe in smaller doses as an adjuvant ..

Anavex’s Blarcamesine works

👍️0

McMagyar 2年前

If you will give a healthy 5 year old an experimental mRNA drug which creates toxic spike proteins in their system..by design! Nonetheless, why wouldn’t you give death sentenced dementia patients a dangerous possibly brain swelling drug that does almost nothing?

The system is broken

👍️0

McMagyar 2年前

This will be the last chance to extricate your financial future from bioscam
And invest in one of these :
Anavex
Cassava
Annovis

Biovie

In that order of magnitude per solution and timing ..in my humble opinion

Or all four..

👍️0

tredenwater2 2年前

Will Biogen drop like a rock by or shoot up by 10 billion come Friday? FDA is in a pickle here. Is there an advisory panel this go around or is this who will weigh in come Friday?

👍️0

tredenwater2 2年前

What a scam! Older article but will take afew years to play out Im sure.

👍️0

tradeherpete 2年前

Biogen Accused of Baiting Patients With Illegal Drug Co-Pays
ByRobert Burnson
September 24, 2021, 9:57 PM EDT

Biogen Inc. was accused by a managed-care provider of illegally boosting sales of its pricey multiple sclerosis drugs by providing them free to patients on a temporary basis and then funneling money to them for co-payments so they can keep taking the medications.

The first part of the scheme involves “seeding” the drugs -- Tysabri, Avonex, and Tecfidera -- to multiple sclerosis sufferers who lacked medical insurance, according to the lawsuit filed Friday by Humana Inc.

After a few months, Biogen encourages the patients to sign up for government-funded healthcare and then funnels “illegal copayment assistance to those same patients under the guise of unrestricted charitable giving,” Humana said.

The money is funneled through a large specialty pharmacy and two medical charities who provide co-pay assistance, according to the suit.

“Given the high costs of the MS drugs here, copays can be thousands of dollars for any single patient,” Humana says in the suit.“But they are a tiny fraction of the total expense for the drugs. This means that if the manufacturer pays the copays itself, it can earn a major return from a minor investment.”

The drugs cost $50,000 to $80,000 a year, according to the suit.

Biogen didn’t respond after regular business hours to a request for comment.

👍️0

Dennisb68 2年前

RGEN is on a run while Biogen is stalled.. Both similar companies,

👍️0

jgrabar 2年前

https://www.marketwatch.com/press-release/grabar-law-office-investigates-claims-on-behalf-of-shareholders-of-biogen-inc-biib-after-it-agrees-to-pay-900-million-for-improper-physician-payments-2022-11-30?siteid=bigcharts&dist=bigcharts&tesla=y

👍️0

tredenwater2 2年前

Unlike the patients heads, the share price “swelling” for Biogen always goes down. Another difference is Biogens Alzheimer’s amyloid platform never dies, just a few of their patients here and there in their trials.

Alzheimer’s is tough, didnt you know, just a little collateral damage, now hurry up and give me approval!

👍️0

McMagyar 2年前

How does this dead dog bounce?
On swelled brains of course

Wouldnt touch bioscam
But agree seller salmoat out

👍️0

conix 3年前

Biogen (NASDAQ:BIIB) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $265.00 price target on the stock, up previously from $235.00.This represents a 23.7% upside from the current price of $214.28

---- Biotechs are due for a run soon....jmo

👍️0

McMagyar 3年前

Phase 4. How many must suffer to pave the linings? When anavex has safe and proved drug available now?
How hateful the crews that say they care about human beings suffering dementia..

You don’t give a shit

👍️0

McMagyar 3年前

Can you imagine the poor bastards that listened to Corey Renauer of motley fool when he said sell Anavex and buy Biogen a few years back?
Can they sue anyone?

What a cruel and twisted effort that was

👍️0

McMagyar 3年前

All the resources these pumpers stole from legitimate chances to save people with dementia..

How much quicker Anavex and others could have moved without this blockaded fraud in their way..

Oxygen and money hole from hell

👍️0

McMagyar 3年前

Thought they were getting bought out today?

What’s worse is

They knew who anavex was and blew up a chance at a deep relationship through what appears to be a poorly handled MTA ..

Still waiting for Wayne State.. pathetic really..

Arrogance and power smell worse than week old sub Saharan carrion..

👍️0

tredenwater2 3年前

Another pump and dump, this time on approval of their drug of all things! Wow, when even approval doesnt work there is some real bad mojo working against you. 3rd or 4 rth cycle of 20 billion that has come and gone. The HFs that own BIIB are making a killing, no pun intended!

👍️0

AAAAMHIM 3年前

$BIIB NEWS!!!! Fasten your SEATBELTS!???????
https://finance.yahoo.com/news/biogen-plans-initiate-phase-3b-113000162.html

👍️0

EHRjunkie 3年前

Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on

https://www.accesswire.com/viewarticle.aspx?id=663682

👍️0

tredenwater2 3年前

Laughable, the pps is one step away from giving up all the fake gains from the announcement of Fda approval for their drug which is still not shown to be efficacious and can be highly toxic for patients including but not limited to death.

OAN Im a little surprised that ihub only allows investors to go back 1 year on the charting….. what gives? Those that forget history are more likely to repeat it. Case in point, I was trying to go back 5 years and look at how Biogen has been overhyped now 3 times for the very close to the exact same amount and has given it all back 2 of the 3 and soon to be 3 for 3 times.

Just an observation.

👍️0

mrplmer 4年前

Pps down $120+ after pumping their bad meds which have no efficacy. Eisai has to break away or go down with the liars. Japanese dont like the bad rep.

👍️0

conix 4年前

STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

By Ed Silverman

The 15-to-0 vote on the Alzheimer's drug Aduhelm amounted to a rebuke of both Biogen and the Food and Drug Administration.

👍️0

Pioneer10257 4年前

Biogen's Aduhelm stumbles at the starting blocks.

https://endpts.com/major-health-systems-refuse-to-administer-aduhelm-as-top-fda-leaders-meet-behind-closed-doors-to-talk-with-payers/

Hi Mrplmer
This company's lack of evidence for it's drug' safety and effectiveness should plunge the stock to nothing I wonder what s keeping it on the 300 hundreds. Everyday's bad news around then and it keeps going up ?

👍️0

mrplmer 4年前

It doesntcome close to Anavex results.

👍️0

AAAAMHIM 4年前

CLOSED EXTREMELY BULLISH INTO close and afterhours. I wouldnt wanna be a short tomorrow.

Listen to a $BIIB patient who's A DOCTOR! MUST WATCH VIDEO. DRUG WORKS! Poor shorts lost their ONLY ammo to bash it. Their KEY bash has expired, now they're reaching for anything. $BIIB can run for a full week+ shorts will lose houses here. Will run $600+.
https://t.co/1xX3cNoMCk

👍️0

mrplmer 4年前

Down 100 pts since they released the dog. FDA needs to redeem themselves from passing on this POS onto the public.

👍️0

tradeherpete 4年前

The fallout has already been widespread. So far, three members of the FDA’s advisory committee have resigned, one of them calling the process a “sham.” Doctors who helped run Biogen’s clinical studies are speaking out, and others are penning editorials that they won’t be prescribing Aduhelm until they see evidence of effectiveness. But no one should hold their breath. When the FDA greenlit Aduhelm for use, it told Biogen it had nine years to run the confirmatory studies necessary to prove Aduhelm’s effectiveness. Nine years of people taking this drug that existing data suggests might not do anything meaningful. With Aduhelm poised to become among the biggest blockbuster drug in history—analysts estimate annual revenues could peak at $10 billion—Biogen probably isn’t in a hurry. But they might not even have to collect that extra data at all (for its part, Biogen said in an email to Slate, “We are working diligently to initiate the confirmatory trial”). Ross, the Yale FDA regulatory expert, looked at FDA approvals from 2005–12, and found that post-market confirmatory studies—ones that truly verified the clinical value of a surrogate outcome—only took place about 10 percent of the time. Despite this dismal compliance rate, according to Ross, the FDA has never fined a company for failing to do a confirmatory study and rarely uses its power to withdraw a drug later shown to be clinically ineffective. In an email to Slate, the FDA did not offer comment on whether it would use its power to withdraw Aduhelm should the drug ultimately prove clinically ineffective but “will carefully monitor trial progress and support efforts to complete this trial in the shortest possible timeline.”

https://slate.com/technology/2021/06/alzheimers-drug-aduhelm-fda-outcomes-plaques.amp

👍️0

polarbear77 4年前

https://slate.com/technology/2021/06/alzheimers-drug-aduhelm-fda-outcomes-plaques.amp

#pathetic

👍️0

mrplmer 4年前

This is a POS. Puts lipstick on pigs and makes drugs that cause brain bleeds.

👍️0

hebbeke47 4年前

https://endpts.com/new-alzheimers-drug-approval-fallout-public-citizen-seeks-removal-of-fdas-woodcock-cavazzoni-and-dunn/

👍️0

Cbdpotential 4年前

https://www.facebook.com/752348178140245/posts/4973596112682076/?d=n

👍️0

Cbdpotential 4年前

http://bit.ly/2O37FjH

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Biogen Inc (BIIB)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

BIIB ニュース

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen Reports Progress on Corporate Responsibility Priorities

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

BIIB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Biogen Inc (BIIB) ニュース

Biogen Inc (BIIB)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

BIIB ニュース

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen Reports Progress on Corporate Responsibility Priorities

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

BIIB Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手